BiomX shareholders approve reverse stock split (1:5-1:10) and 2019 plan amendment

BiomX Inc.

Special meeting held August 28, 2023; both proposals passed.
Proposal 1: amendment to 2019 incentive plan to allow option exchanges — 25,795,338 for, 237,665 against.
Proposal 2: authorize board to effect reverse stock split at ratio between 1:5 and 1:10 — 30,686,906 for, 232,624 against.
Proposal 1 had 4,886,229 broker non-votes; Proposal 2 had none.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

BiomX Inc. shareholders approved Approval of an amendment to the Company's 2019 incentive plan to allow the board to effect one or more option exchanges at the 2023-08-28 meeting.

Outcome: passed
Meeting: 2023-08-28

Exact text from the filing

Proposal No. 1- Approval of an amendment to the Company's 2019 incentive plan to allow the board to effect one or more option exchanges.

View on SEC.gov

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

BiomX Inc. shareholders approved Authorization of the Company's board of directors to amend the certificate of incorporation to effect a reverse stock split of the Company's outstanding Common Stock at any ratio between 1-for-5 and 1-for-10 at the 2023-08-28 meeting.

Proposal: reverse split
Outcome: passed
Meeting: 2023-08-28

Exact text from the filing

Proposal No. 2- Authorization of the Company's board of directors to amend the certificate of incorporation to effect a reverse stock split of the Company's outstanding Common Stock at any ratio between 1-for-5 and 1-for-10.

View on SEC.gov

224 shareholder votes filed in the last 30 days. Browse all shareholder votes →

BiomX Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-071719

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.